Literature DB >> 69882

Elevation of plasma-prolactin by monoamine-oxidase inhibitors.

S L Slater, S Lipper, D J Shiling, D L Murphy.   

Abstract

Plasma-prolactin levels doubled in depressive patients treated with the monoamine-oxidase inhibitors, clorgyline and pargyline. The absence of significant changes in plasma-cortisol in the same patients suggests that the increases in prolactin are not attributable to non-specific effects of stress.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 69882     DOI: 10.1016/s0140-6736(77)90956-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  7 in total

Review 1.  Medical management of prolactin-secreting pituitary adenomas.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

Review 2.  Antidepressant-induced hyperprolactinaemia: incidence, mechanisms and management.

Authors:  Flora Coker; David Taylor
Journal:  CNS Drugs       Date:  2010-07       Impact factor: 5.749

3.  Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers.

Authors:  M Koulu; M Scheinin; A Kaarttinen; J Kallio; K Pyykkö; J Vuorinen; R H Zimmer
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

Review 4.  Drug-induced changes in prolactin secretion. Clinical implications.

Authors:  K Hell; H Wernze
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec

5.  Effect of a reversible and selective MAO-A inhibitor (cimoxatone) on diurnal variation in plasma prolactin level in man.

Authors:  M Strolin Benedetti; A Eschalier; A Lesage; G Dordain; V Rovei; E Zarifian; P Dostert
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 6.  Drugs and prolactin.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

7.  Pharmacological causes of hyperprolactinemia.

Authors:  Daria La Torre; Alberto Falorni
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.